Exemples concrets d'une collaboration fructueuse avec les patients // Concrete voorbeelden van impactvolle samenwerking met patiënten

Point de vue de l'industrie pharmaceutique //Standpunt van de pharmaceutische industrie



25 Septembre 2018



Aperçu



Point de vue general de l'industrie pharmaceutique sur l'importance de la collaboration avec les patients dans le développement clinique d'un médicament

Nathalie Lambot, Expert Santé Publique- pharma.be

Exemples concrets par les membres de pharma.be

Edel Hendrickx, Clinical Study Unit Country Head in Belgium at Sanofi **Patricia Van Rompuy,** Clinical R&D Director, Global Clinical Operations, Benelux at Janssen, Pharmaceutical Companies of Johnson and Johnson



Point de vue general de l'industrie pharmaceutique sur l'importance de la collaboration avec les patients dans le développement clinique d'un médicament




Nathalie Lambot

Expert Santé Publique- pharma.be


La Belgique est un des leaders européens en matière d'essais cliniques



Percentage of clinical trials in Europe conducted in Belgium



Total population of Belgium relative to the total population of the European Union in 2016




Travailler « pour et avec les patients » dans le cadre des essais cliniques est un élément clé pour notre pays.

Les patients peuvent être impliqués tout au long du processus de R&D des médicaments



Patient involvement in medicines R&D




Source: https://www.eupati.eu/

www.eupati.eu

L'implication des patients est implémentée au niveau global ou au niveau regional d'une compagnie





Renforcer la centralité du patient dans les essais cliniques est un objectif partagé



L'industrie et les organisations de patients s'engagent à la transparence et partagent dès lors entre elles les méthodes centrées sur les patients





Académie européenne des patients

Patient centricity: what is it and how to make it meaningful?
| Roundtable discussion at DIA EuroMeeting





PATIENTS AS PARTNERS EUROPE SAVE THE DATE! JANUARY 23-24, 2018 RADISSON BLU PORTMAN HOTEL, LONDON, UK


Concrete voorbeelden van impactvolle samenwerking met patiënten



Edel Hendrickx

Clinical Study Unit Country Head in Belgium at Sanofi







Introducing Sanofi

Life is a health journey and Sanofi is there beside people as a health journey partner. We are focused on human health, operating worldwide and transforming scientific innovation into healthcare solutions across a broad spectrum of health conditions.

5 global business units

- Vaccines with Sanofi Pasteur
- Specialty care, rare diseases, multiple sclerosis, oncology and immunology – with Sanofi Genzyme
- Diabetes and cardiovascular diseases
- General medicines and emerging markets
- Consumer healthcare reinforced in 2017 with the teams of Boehringer Ingelheim

Sanofi at a glance

100,000+

EMPLOYEES

145

NATIONALITIES

100

COUNTRIES

Keys figures in 2017





€ 6,964 M BUSINESS NET INCOME


CORPORATE PRESENTATION | MARCH 2018



⁽¹⁾ World excluding U.S., Canada, Western & Eastern Europe (except Eurasia), Japan, South Korea, Australia, New Zealand and Puerto Rico.


⁽²⁾ Western Europe + Eastern Europe (except Eurasia: Russia, Ukraine, Georgia, Belarus, Armenia and Turkey).

⁽³⁾ Japan, South Korea, Canada, Australia, New Zealand, Puerto Rico.





How to improve our collaboration?





Patient Expert Forum ReumaNet – Sanofi August 2018

Edel Hendrickx, Clinical study Unit Country Head Sanofi



Patient Expertise Centrum Reuma



Innovative patient empowerment concept launched by REUMANET.be




Core idea: high quality patient expertise represents a value (that can be monetised):

- Coaching and education of other patients (P2P)
- Participation in the multidisciplinary care team
- Professional services geared towards stakeholders (government, care providers, sick funds, industry, ...)

Dedicated training for patient experts, in collaboration with vzw Trefpunt Zelfhulp. Scope:

 Work & school, symptom management, treatment management, family, lifestyle, administrative support



- Aligned with EUPATI, the European Patient Academy for Therapeutic Innovation
- PECs in other therapeutic areas are in preparation, or under discussion



Reumanet Patient Expert and sanofi Forum

- PEC-R fits with Sanofi's global patient centricity programs aimed at capturing patients' real-world experiences and insights to help Sanofi's endeavors, from identifying research priorities and developing our products to shaping patient programs.
- First Patient Expert Forum as a pilot project under PEC-R in August 2018.
- Brought together trained patient-experts and Sanofi employees from across the Belgian organisation to discuss and validate company approaches to patient information and communication
- Specific aims:
 - Receive feedback on relevance and user-friendliness of patient information, patient services and digital apps for reumatoid arthritis patients
 - Validate patient communication tools in the context of clinical trials launched in Belgian hospitals
 - To discuss broader concepts like patient recruitment in clinical trials and digital health



Learning points

- General initial learnings:
 - · dialogue appreciated by both sides;
 - valuable insights gathered;
 - dialogue will likely repeated
- Learning points for the clinical trial unit for the informed consent form and investigational product information leaflet
 - Avoid difficult language or explain better
 - Make it not too long
 - Give clear information on the rationale of the study
 - Use more pictures
 - Clarify more why a patient should participate
 - Group information per topic in the form
 - Communicate the results of the trial after the study to the study patients
- Feedback will be given to ReumaNet on what points we have worked on







Concrete voorbeelden van impactvolle samenwerking met patiënten



Patricia Van Rompuy

Clinical R&D Director, Global Clinical Operations, Benelux at Janssen, Pharmaceutical Companies of Johnson and Johnson









JANSSEN PATIENT ENGAGEMENT

We partner with patients and caregivers, systematically interacting directly with them. We act on patient perspectives early and maintain an ongoing dialogue to develop solutions that better meet needs.




Patients are involved early and shaping solutions



Modifications to a Clinical Trial

Outcome: No dropouts



Updated Target Product Profile

Outcome: Pursuing ways to know sooner whether a treatment will work

